Consensus Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-17 pm EDT			5-day change	1st Jan Change
52.86 ^USD	+2.18%		-6.79%	+20.00%

Jul. 07	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 11	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE

Evolution of the Average Target: Scholar Rock Holding Corporation

Evolution of the Target Price: Scholar Rock Holding Corporation

Changes in Analyst Recommendations: Scholar Rock Holding Corporation

50b0b7138520f2f89.cEdNhZSUJiTNcZFfL7bmlKjc6A-Er2sIj0wx1i6oA60.MQY33aPTVWagMtkWYNTT9ZmYpGDb9zpcvwEGpGHrW94XFC7v2eZfEYA_4g~4809bca3520f07f8eaac7a0ce0df3c9a

Analysts' recommendations: Scholar Rock Holding Corporation

Apr. 21	Canaccord Genuity Initiates Scholar Rock at Buy With $62 Price Target	MT
Mar. 31	Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating	MT
Mar. 04	Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating	MT
Mar. 03	Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating	MT
Jan. 07	UBS Initiates Scholar Rock Holding at Buy With $60 Price Target	MT
Nov. 14	Wedbush Adjusts Pt on Scholar Rock Holding to $50 From $43, Maintains Outperform Rating	MT
25-09-23	HC Wainwright Adjusts Price Target on Scholar Rock Holding to $44 From $50, Maintains Buy Rating	MT
25-09-23	Scholar Rock's Apitegromab Approval Still Likely Despite Delay, Wedbush Says	MT
25-09-17	Barclays Initiates Scholar Rock at Overweight With $45 Price Target	MT
25-09-15	Leerink Partners Initiates Scholar Rock at Outperform With $51 Price Target	MT
25-08-06	Biopharma Scholar Rock Q2 net loss widens, no revenue	RE
25-07-18	Truist Raises Price Target on Scholar Rock Holding to $54 From $45, Keeps Buy Rating	MT
25-07-17	Cantor Fitzgerald Initiates Coverage on Scholar Rock With Overweight Rating	MT
25-02-27	Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating	MT
24-11-25	Wedbush Raises Price Target on Scholar Rock to $47 From $40, Maintains Outperform Rating	MT
24-11-25	Truist Securities Adjusts Price Target on Scholar Rock to $45 From $36, Maintains Buy Rating	MT
24-11-12	Wedbush Raises Price Target on Scholar Rock to $40 From $37, Maintains Outperform Rating	MT
24-10-08	Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says	MT
24-10-07	Scholar Rock's Phase 3 Apitegromab Trial in Spinal Muscular Atrophy Meets Primary Endpoint	MT
24-10-07	Wedbush Raises Price Target on Scholar Rock Holding to $27 From $25, Keeps Outperform Rating	MT
24-10-07	Truist Raises Price Target on Scholar Rock Holding to $36 From $20, Keeps Buy Rating	MT
24-09-27	Wedbush Raises Price Target on Scholar Rock to $25 From $23, Keeps Outperform Rating	MT
24-06-13	BMO Capital Raises Price Target on Scholar Rock to $31 From $29, Maintains Outperform Rating	MT
24-03-28	Raymond James Initiates Scholar Rock With Strong Buy Rating, $30 Price Target	MT
23-10-25	Jefferies Upgrades Scholar Rock to Buy From Hold, Adjusts Price Target to $20 From $7	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SCHOLAR ROCK HOLDING CORPORATION					+12.21%
	ARGENX SE					+17.91%
	WUXI APPTEC CO., LTD.					+27.64%
	INSMED INCORPORATED					+81.3%
	BIONTECH SE					+33.1%
	WUXI BIOLOGICS (CAYMAN) INC.					+27.13%
	GENMAB A/S					+24.84%
	PHARMAESSENTIA CORPORATION					-10.18%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+14.72%
	EXELIXIS, INC.					-8.92%
	Average					+21.97%
	Weighted average by Cap.					+25.24%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

52.86USD

Average target price

59.31USD

Spread / Average Target

+12.21%

High Price Target

70.00USD

Spread / Highest target

+32.43%

Low Price Target

48.00USD

Spread / Lowest Target

-9.19%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Canaccord Genuity
Wedbush
Truist Securities
UBS
HC Wainwright
Barclays
Leerink Partners
Cantor Fitzgerald
BMO Capital
Raymond James
Jefferies & Co.
Piper Sandler
JPMorgan Chase